Literature DB >> 27546479

Tacrolimus prevents murine cerebral malaria.

Lam Quoc Bao1,2, Dang My Nhi1, Nguyen Tien Huy3, Shinjiro Hamano2, Kenji Hirayama1.   

Abstract

Tacrolimus and mycophenolate mofetil are immunosuppressants frequently used in human organ transplantation. Tacrolimus is also reported to inhibit Plasmodium falciparum growth in vitro. Here, we report that tacrolimus prevented the death from cerebral malaria of Plasmodium berghei ANKA-infected C57BL/6J mice, but not their death from malaria due to the high parasitaemia and severe anaemia. The mycophenolate mofetil-treated mice showed higher mortality from cerebral malaria and succumbed to malaria earlier than tacrolimus-treated littermates. Tacrolimus attenuated the infiltration of mononuclear cells including pathogenic CD8+ T cells into the brain. It appears to prevent murine cerebral malaria through the inhibition of cerebral infiltration of CD8+ T cells.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD8+ T cells; experimental cerebral malaria; prevention; sequestration; tacrolimus

Mesh:

Substances:

Year:  2016        PMID: 27546479      PMCID: PMC5213038          DOI: 10.1111/imm.12661

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria.

Authors:  Irene Gramaglia; Peter Sobolewski; Diana Meays; Ramiro Contreras; John P Nolan; John A Frangos; Marcos Intaglietta; Henri C van der Heyde
Journal:  Nat Med       Date:  2006-11-12       Impact factor: 53.440

2.  Early activation of microglia in the pathogenesis of fatal murine cerebral malaria.

Authors:  I M Medana; N H Hunt; T Chan-Ling
Journal:  Glia       Date:  1997-02       Impact factor: 7.452

3.  The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria.

Authors:  M B van Hensbroek; A Palmer; E Onyiorah; G Schneider; S Jaffar; G Dolan; H Memming; J Frenkel; G Enwere; S Bennett; D Kwiatkowski; B Greenwood
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

4.  Immunosuppression with FK506 increases bone induction in demineralized isogeneic and xenogeneic bone matrix in the rat.

Authors:  G Voggenreiter; S Assenmacher; E Kreuzfelder; M Wolf; M R Kim; D Nast-Kolb; F U Schade
Journal:  J Bone Miner Res       Date:  2000-09       Impact factor: 6.741

5.  Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor.

Authors:  G E Grau; H Heremans; P F Piguet; P Pointaire; P H Lambert; A Billiau; P Vassalli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

Review 6.  Breaking down the blood-brain barrier: signaling a path to cerebral malaria?

Authors:  Sue Adams; Heidi Brown; Gareth Turner
Journal:  Trends Parasitol       Date:  2002-08

7.  Accumulation of Plasmodium berghei-infected red blood cells in the brain is crucial for the development of cerebral malaria in mice.

Authors:  Fernanda G Baptista; Ana Pamplona; Ana C Pena; Maria M Mota; Sylviane Pied; Ana M Vigário
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

8.  Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria.

Authors:  W McGuire; A V Hill; C E Allsopp; B M Greenwood; D Kwiatkowski
Journal:  Nature       Date:  1994-10-06       Impact factor: 49.962

Review 9.  Artemisinin-based combination therapy for treating uncomplicated malaria.

Authors:  David Sinclair; Babalwa Zani; Sarah Donegan; Piero Olliaro; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Critical role of the neutrophil-associated high-affinity receptor for IgE in the pathogenesis of experimental cerebral malaria.

Authors:  Adeline Porcherie; Cedric Mathieu; Roger Peronet; Elke Schneider; Julien Claver; Pierre-Henri Commere; Hélène Kiefer-Biasizzo; Hajime Karasuyama; Geneviève Milon; Michel Dy; Jean-Pierre Kinet; Jacques Louis; Ulrich Blank; Salaheddine Mécheri
Journal:  J Exp Med       Date:  2011-10-03       Impact factor: 14.307

View more
  1 in total

1.  Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets.

Authors:  Reagan M Mogire; Hoseah M Akala; Rosaline W Macharia; Dennis W Juma; Agnes C Cheruiyot; Ben Andagalu; Mathew L Brown; Hany A El-Shemy; Steven G Nyanjom
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.